An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment
Phase of Trial: Phase IV
Latest Information Update: 27 Sep 2019
Price : $35 *
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia; Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 18 May 2019 Status changed from active, no longer recruiting to recruiting.
- 08 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 18 May 2018 Planned End Date changed from 21 Jun 2024 to 21 Apr 2023.